Akero Therapeutics Past Earnings Performance

Past criteria checks 0/6

Akero Therapeutics's earnings have been declining at an average annual rate of -24.9%, while the Biotechs industry saw earnings growing at 7.7% annually.

Key information

-24.9%

Earnings growth rate

8.7%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth raten/a
Return on equity-32.1%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Akero Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:0K4 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-23738232
30 Jun 240-20436198
31 Mar 240-17933171
31 Dec 230-15231142
30 Sep 230-12030107
30 Jun 230-1163393
31 Mar 230-1123187
31 Dec 220-1123085
30 Sep 220-1212895
30 Jun 220-1102189
31 Mar 220-1122092
31 Dec 210-1011982
30 Sep 210-981880
30 Jun 210-951878
31 Mar 210-821667
31 Dec 200-791565
30 Sep 200-651452
30 Jun 200-591349
31 Mar 200-501142
31 Dec 190-44937
30 Sep 190-90726
30 Jun 190-86513
31 Mar 190-87316
31 Dec 180-82212
30 Sep 180-22111

Quality Earnings: 0K4 is currently unprofitable.

Growing Profit Margin: 0K4 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0K4 is unprofitable, and losses have increased over the past 5 years at a rate of 24.9% per year.

Accelerating Growth: Unable to compare 0K4's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0K4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 0K4 has a negative Return on Equity (-32.13%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 05:53
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Akero Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Alexandria HammondBofA Global Research
Edward NashCanaccord Genuity